| Objective Analysis and Clinical Significance of the Spatial Tumor-Infiltrating Lymphocyte Patterns in Non-Small Cell Lung Cancer ML de Rodas, Y Wang, G Peng, J Gu, M Mino-Kenudson, JW Riess, ... Clinical cancer research: an official journal of the American Association …, 2024 | | 2024 |
| Objective Analysis and Clinical Significance of the Spatial Tumor-Infiltrating Lymphocyte Patterns in Non–Small Cell Lung Cancer M Lopez de Rodas, Y Wang, G Peng, J Gu, M Mino-Kenudson, JW Riess, ... Clinical Cancer Research 30 (5), 998-1008, 2024 | | 2024 |
| Immune-related colitis is associated with fecal microbial dysbiosis and can be mitigated by fecal microbiota transplantation A Elkrief, NR Waters, N Smith, A Dai, J Slingerland, N Aleynick, B Febles, ... Cancer Immunology Research 12 (3), 308-321, 2024 | 1 | 2024 |
| Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer D Memon, AJ Schoenfeld, D Ye, G Fromm, H Rizvi, X Zhang, MR Keddar, ... Cancer Cell, 2024 | 8 | 2024 |
| Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD (L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer (vol 28, pg 978, 2023) A Elkrief, B Ricciuti, J Alessi, T Fei, HL Kalvin, J Egger, H Rizvi, ... ONCOLOGIST 29 (1), e166-e166, 2024 | | 2024 |
| Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors SP Patel, T Alonso-Gordoa, S Banerjee, D Wang, J Naidoo, NE Standifer, ... Journal for ImmunoTherapy of Cancer 12 (2), 2024 | 2 | 2024 |
| Erratum to" Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project":[Annals of … DM Vega, LM Yee, LM McShane, PM Williams, L Chen, T Vilimas, ... Annals of oncology: official journal of the European Society for Medical …, 2024 | | 2024 |
| P2. 07-03 Factors Associated with Disease Progression after Discontinuation of Immunotherapy for Immune-Related Toxicity in Non-small Cell Lung Cancer F Pecci, R Thummalapalli, S Alden, B Ricciuti, JV Alessi, A Elkrief, H Rizvi, ... Journal of Thoracic Oncology 18 (11), S323-S324, 2023 | | 2023 |
| P1. 21-12 Microsatellite Instability Defines a Subset of Lung Cancers with Smoking Exposure, High Tumor Mutational Burden and MLH1 Inactivation SR Yang, E Gedvilaite, R Ptashkin, J Chang, J Ziegler, D Mata, ... Journal of Thoracic Oncology 18 (11), S239, 2023 | | 2023 |
| Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer A Elkrief, B Ricciuti, JV Alessi, T Fei, HL Kalvin, JV Egger, H Rizvi, ... The Oncologist 28 (11), 978-985, 2023 | 3 | 2023 |
| Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer R Thummalapalli, B Ricciuti, C Bandlamudi, D Muldoon, H Rizvi, A Elkrief, ... Clinical Cancer Research 29 (21), 4408-4418, 2023 | 3 | 2023 |
| The GENIE BPC NSCLC Cohort: A Real-World Repository Integrating Standardized Clinical and Genomic Data for 1,846 Patients with Non–Small Cell Lung Cancer NJ Choudhury, JA Lavery, S Brown, I de Bruijn, J Jee, TN Tran, H Rizvi, ... Clinical Cancer Research 29 (17), 3418-3428, 2023 | 8 | 2023 |
| Clinical benefit from immunotherapy in patients with SCLC is associated with tumor capacity for antigen presentation CM Rudin, D Balli, WV Lai, AL Richards, E Nguyen, JV Egger, ... Journal of Thoracic Oncology 18 (9), 1222-1232, 2023 | 19 | 2023 |
| Intratumoral immune triads are required for adoptive T cell therapy-mediated elimination of solid tumors G Espinosa-Carrasco, A Scrivo, P Zumbo, A Dave, D Betel, M Hellmann, ... bioRxiv, 2023 | 3 | 2023 |
| Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/Keyimpact trial interim results M Gutierrez, WS Lam, MD Hellmann, MA Gubens, C Aggarwal, DSW Tan, ... Nature Medicine 29 (7), 1718-1727, 2023 | 7 | 2023 |
| Fecal microbiota transplantation for refractory immune-checkpoint-inhibitor colitis. A Elkrief, W Nicholas, N Smith, A Dai, JB Slingerland, N Aleynick, ... Journal of Clinical Oncology 41 (16_suppl), 2657-2657, 2023 | 2 | 2023 |
| Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer A Ravi, MD Hellmann, MB Arniella, M Holton, SS Freeman, V Naranbhai, ... Nature genetics 55 (5), 807-819, 2023 | 39 | 2023 |
| Baseline radiomic signature to estimate overall survival in patients with NSCLC L Dercle, M Fronheiser, NA Rizvi, MD Hellmann, S Maier, W Hayes, ... Journal of Thoracic Oncology 18 (5), 587-598, 2023 | 7 | 2023 |
| Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade JA Pai, MD Hellmann, JL Sauter, M Mattar, H Rizvi, HJ Woo, N Shah, ... Cancer Cell 41 (4), 776-790. e7, 2023 | 28 | 2023 |
| Background variability in plasma ctDNA levels in patients with advanced lung cancer in the absence of treatment DM Vega, A Markovets, C Abbosh, K Quinn, K Chang, S Wienke, ... Cancer Research 83 (7_Supplement), 1052-1052, 2023 | | 2023 |
